Just noticed Wells Fargo jumped into coverage of Rapport Therapeutics back in early February with an overweight call. Biotech stock RAPP is getting some serious analyst attention right now.

The price target picture is pretty interesting - analysts are looking at an average of $53.30, which would be about 91% upside from where it was trading around $28. Some are more bullish at $84, others more conservative at $40. That kind of spread tells you there's still a lot of uncertainty, but the overweight lean suggests more upside optimism than not.

What's catching my eye is the fund activity. Over 210 institutions are holding positions, and they've been adding. Institutional ownership jumped 26% in the last three months to over 51 million shares. The big holders - Trv Group, Arch Venture, Capital International - are all sitting on massive stakes. Goldman Sachs actually increased their position by 49% last quarter, which is a pretty aggressive move. Cormorant and Capital International also ramped up significantly. When you see multiple large funds going overweight like this, it usually means they're seeing something worth betting on.

The put/call ratio is sitting at 0.15, which is pretty bullish - way more call buying than puts. Feels like there's real conviction behind this coverage push. Definitely one to keep on the radar if you're looking at biotech plays.